Insulin resistance, leptin and monocyte chemotactic protein-1 levels in diabetic and non-diabetic Afro-Caribbean subjects

Archives of Physiology and Biochemistry

Volumn 115, Issue 1, 2009, Pages 22-27

  Ezenwaka, C E ^a   Nwagbara, E ^b   Seales, D ^a   Okali, F ^b   Sell, H ^c   Eckel, J ^c  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b Tobago Regional Health Authority   (Trinidad and Tobago)

^c LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Afro Caribbean; Coronary heart disease; Insulin resistance; Metabolic syndrome; Monocyte chemotactic protein 1; Obesity; Type 2 diabetes

Indexed keywords

LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

AFRICA; AGED; ANIMAL; ARTICLE; BLOOD; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RACE; TRINIDAD AND TOBAGO;

AFRICA; AGED; ANIMALS; CHEMOKINE CCL2; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; TRINIDAD AND TOBAGO;

EID: 62349116540     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450802676343     Document Type: Article

References (30)

1. Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M. (2007). Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 145: 52-5.
2. Al-Daghri N, Al-Rubean K, Bartlett WA, Al-Attas O, Jones AF, Kumar S. (2003). Serum leptin is elevated in Saudi Arabian patients with metabolic syndrome and coronary artery disease. Diabet Med 20: 832-837.
3. Alberti KG, Zimmet P, Shaw J. (2006). Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23(5):469-480.
4. Al-Daghri NM, Al-Attas OS, Al-Rubeaan K, Mohieldin M, Alkatari M, Jones AF, Kumar S. (2007). Serum leptin and its relation to anthropometric measures of obesity in pre-diabetic Saudis. Cardiovasc Diabetol 6: 18.
5. Buyukbese MA, Cetinkaya A, Kocabas R, Guven A, Tarakcioglu M. (2004). Leptin levels in obese women with and without type 2 diabetes mellitus. Mediators Inflamm 13(5/6): 321-325.
6. Castracane VD, Henson MC. (2002). When did leptin become a reproductive hormone? Semin Reprod Med 20: 89-92.
7. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL. (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334(5): 292-5.
8. DECODE Study Group. (1999). Glucose tolerance and mortality: comparison of WHO and American Diabetes Association Diagnostic criteria. Lancet 354: 617-21.
9. Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, Mohan V. (2006). Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein-1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 55(9): 1232-8.
10. DeFronzo RA, Ferrannini E. (1991). Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14(3): 173-94.
11. Ezenwaka CE, Nwagbara E, Seales D, Okali F, Hussaini S, Raja Bn, Sell H, Avci H, Eckel J. (2007). A comparative study of the prevalence of components of the metabolic syndrome in type 2 diabetic patients in two Caribbean Islands using the New International Diabetes Federation definition. Arch Physiol Biochem 113(4/5): 202-10.
12. Ezenwaka CE, Offiah NV. (2002). Differences in cardiovascular disease risk factors in elderly and younger patients with type 2 diabetes in the West Indies. Singapore Med J 43(10): 497-503.
13. Farin HM, Abbasi F, Reaven GM. (2006). Body mass index and waist circumference both contribute to differences in insulin-mediated glucose disposal in nondiabetic adults. Am J Clin Nutr 83(1): 47-51.
14. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. (2002). Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51(4): 1131-7.
15. Hardie L, Trayhurn P, Abramovich D, Fowler P. (1997). Circulating leptin in women: a longitudinal study in the menstrual cycle and during pregnancy. Clin Endocrinol (Oxf) 47(1): 101-6.
16. Havel PJ, Kasim-Karakas S, Dubuc GR, Mueller W, Phinney SD. (1996). Gender differences in plasma leptin concentrations. Nat Med 2(9): 949-50.
17. International Diabetes Federation. (2006). IDF World-wide definition of the metabolic syndrome. Available from: www. idf. org/metabolic-syndrome (accessed 19 December 2006).
18. Lichnovska R, Gwozdziewiezova A, Hrebicek J. (2002). Gender differences in factors influencing insulin resistance in elderly hyperlipemic non-diabetic subjects. Cardiovasc Diabetol 1: 4.
19. Maruyama-Furuta N, Yano Y, Gabazza EC, Suematu M, Matsumoto K, Akatsuka H, Bruno NE, Araki R, Katsuki A, Sumida Y. (2007). Monocyte chemoattractant protein-1 promoter-2518 polymorphism is associated with post-challenge insulin and glucosa levels in non-diabetic Japanese subjects. Diabetes Res Clin Pract 78(2): 208-10.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. (1985). Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-19.
21. Minakar KL. 1987. Aging and diabetes mellitus as risk factors for vascular disease. Am J Med 82(Suppl. 1B): 47-53.
22. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. (2000). Signifcance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 121: 437-43.
23. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3): 327-34.
24. Reaven GM. (1988). Role of insulin resistance in human disease. Diabetes 37(12): 1595-607.
25. Rosenbaum M, Nicolson M, Hirsch J, Heymsfield SB, Gallagher D, Chu F, Leibel RL. (1996). Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 81(9): 3424-7.
26. Sartipy P, Loskutoff DJ. (2003). Monocyte chemoattractant protein-1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100: 7265-70.
27. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. (2006). Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 147(5): 2458-67.
28. Shimokata H, Muller DC, Fleg JL, Sorkin J, Ziemba AW, Andres R. (1991). Age as independent determinant of glucose tolerance. Diabetes 40: 44-50.
29. Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S, Marco C, Caro JF. (1996). Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 97(5): 1344-7.
30. Takahashi K, Mizuarai S, Araki H, Mashiko S, Ishihara A, Kanatani A, Itadani H, Kotani H. (2003). Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 278: 46654-60.